A new trading day began on Tuesday, with Candel Therapeutics Inc (NASDAQ: CADL) stock price up 5.19% from the previous day of trading, before settling in for the closing price of $9.05. CADL’s price has ranged from $1.34 to $14.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -25.00%. Meanwhile, its annual earnings per share averaged -11.83%. With a float of $30.51 million, this company’s outstanding shares have now reached $32.13 million.
Let’s determine the extent of company efficiency that accounts for 42 employees. In terms of profitability, gross margin is 54.28%, operating margin of -2001.58%, and the pretax margin is -2939.13%.
Candel Therapeutics Inc (CADL) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Candel Therapeutics Inc is 31.41%, while institutional ownership is 36.03%. The most recent insider transaction that took place on Jan 15 ’25, was worth 97,783. In this transaction Chief Scientific Officer of this company sold 13,534 shares at a rate of $7.22, taking the stock ownership to the 110,673 shares. Before that another transaction happened on Jan 15 ’25, when Company’s Chief Technology Officer sold 14,322 for $7.22, making the entire transaction worth $103,476. This insider now owns 96,790 shares in total.
Candel Therapeutics Inc (CADL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.83% per share during the next fiscal year.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Here are Candel Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -1.16 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Looking closely at Candel Therapeutics Inc (NASDAQ: CADL), its last 5-days average volume was 0.92 million, which is a drop from its year-to-date volume of 1.16 million. As of the previous 9 days, the stock’s Stochastic %D was 85.54%. Additionally, its Average True Range was 0.70.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 53.03%, which indicates a significant decrease from 80.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.93% in the past 14 days, which was lower than the 149.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.65, while its 200-day Moving Average is $6.86. However, in the short run, Candel Therapeutics Inc’s stock first resistance to watch stands at $10.08. Second resistance stands at $10.64. The third major resistance level sits at $11.04. If the price goes on to break the first support level at $9.12, it is likely to go to the next support level at $8.72. Now, if the price goes above the second support level, the third support stands at $8.16.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
With a market capitalization of 423.40 million, the company has a total of 32,476K Shares Outstanding. Currently, annual sales are 0 K while annual income is -37,940 K. The company’s previous quarter sales were 0 K while its latest quarter income was -10,650 K.
